Open AccessRisk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry‐based cohort study
Author(s) -
Liapis Konstantinos,
Vrachiolias Georgios,
Papadopoulos Vasileios,
Kourakli Alexandra,
Galanopoulos Athanasios G.,
Papoutselis Menelaos,
Papageorgiou Sotirios G.,
Diamantopoulos Panagiotis T.,
Pappa Vassiliki,
Viniou NoraAthina,
Vassilakopoulos Theodoros P.,
Hatzimichael Eleftheria,
Bouronikou Eleni,
Ximeri Maria,
Pontikoglou Charalambos,
Panayiotidis Panayiotis,
Karakatsanis Stamatis,
Vardi Anna,
Symeonidis Argiris,
Kotsianidis Ioannis
Publication year - 2020
Publication title -
ejhaem
Language(s) - English
Resource type - Journals
ISSN - 2688-6146
DOI - 10.1002/jha2.30
Subject(s) - medicine , disease , myelodysplastic syndromes , psychological intervention , cohort , cause of death , intensive care medicine , bone marrow , psychiatry
Cardiovascular disease (CVD) emerges as a major cause of death in patients with myelodysplastic syndrome (MDS), but predictors of fatal CVD and the effect of MDS‐specific treatments on CVD mortality remain largely unknown. In an analysis involving 831 patients with MDS with known causes of death, we noted an independent association of lower risk MDS, age >70 years, pre‐existing CVD, and treatment with erythropoiesis‐stimulating agents with a higher risk of death from CVD. If externally validated, these simple risk factors could increase clinicians’ awareness toward CVD complications and guide early introduction of intensive monitoring and preventive interventions in MDS patients.